Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 666 | 344 | 1,208 | 735 | 2,640 |
| Marketable Securities | 43 | 35 | 35 | 36 | 40 |
| Receivables | 847 | 406 | 376 | 421 | 236 |
| TOTAL | $1,556 | $785 | $1,619 | $1,192 | $2,916 |
| Non-Current Assets | |||||
| PPE Net | 63 | 72 | 77 | 88 | 85 |
| Investments And Advances | 23 | 23 | 22 | 23 | 22 |
| Other Non-Current Assets | 42 | 104 | 123 | 143 | 162 |
| TOTAL | $128 | $199 | $222 | $254 | $269 |
| Total Assets | $1,684 | $984 | $1,841 | $1,446 | $3,185 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,203 | 3,783 | 3,508 | 4,535 | 3,459 |
| TOTAL | $2,203 | $3,783 | $3,508 | $4,535 | $3,459 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 3,849 | 1,412 |
| TOTAL | $N/A | $19 | $36 | $3,904 | $1,485 |
| Total Liabilities | $2,203 | $3,802 | $3,544 | $8,439 | $4,944 |
| Shareholders' Equity | |||||
| Retained earnings | -41,369 | -34,530 | -32,382 | -31,525 | -26,121 |
| TOTAL | $-519 | $-2,818 | $-1,703 | $-6,993 | $-1,759 |
| Total Liabilities And Equity | $1,684 | $984 | $1,841 | $1,446 | $3,185 |